Academy Sports + Outdoors Reports Second Quarter Fiscal 2026 Results
Source: globenewswire.com

Academy Sports and Outdoors reported Q2 diluted GAAP EPS of $2.17, up 17.3% year over year, and adjusted EPS of $2.31, up 19.1%, including a net $0.06-per-share tariff-refund benefit after reinvestments. Total sales grew 3.0%, while comparable sales declined 0.4%; e-commerce sales increased 12.8% and new-store comparable sales rose by a positive mid-single-digit percentage. The company opened three stores in Pennsylvania and Tennessee, affirmed its sales outlook, and raised EPS guidance.
Analysis
The key underwriting issue is whether ASO can convert unit growth and digital traffic into mature-store productivity before fixed occupancy, labor and fulfillment costs dilute returns. Negative comparable sales alongside an EPS beat suggests earnings quality is partly timing- and non-operating-item-sensitive rather than evidence of broad demand acceleration; the tariff-related benefit should not be annualized. A raised outlook can support the shares over the next 1-3 months, but the multiple expansion case requires sequential comp improvement and sustained merchandise-margin resilience once the benefit rolls off.
ASO's new-store strategy is most disruptive to regional sporting-goods independents and, at the margin, HIBB; it is less threatening to DKS, whose premium assortment, services and urban footprint diversify its demand base. The more relevant second-order risk is promotional response: if DKS, WMT or AMZN lean into holiday sporting goods, ASO's value positioning may protect traffic but force gross-margin giveback. E-commerce growth is constructive only if fulfillment economics improve; sales growth through digital channels without lower shipping expense or higher basket size would be earnings-dilutive.
Consensus may over-credit the guidance increase without separating recurring operating leverage from the tariff refund and associated reinvestment. Near term, the market may reward execution and new-unit momentum; over 6-18 months, the thesis depends on store-level cash returns, inventory turns and comp recovery rather than headline sales growth. Falsification would be another negative comp quarter, gross-margin contraction despite lower markdowns, or inventory growth materially outpacing sales into the holiday period.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
Key Decisions for Investors
- Maintain a tactical long ASO only on post-earnings consolidation rather than chase opening strength; target a 1-3 month hold into holiday updates. Require evidence of positive sequential comparable-sales momentum and stable gross margin; exit if management cuts holiday guidance or inventories outgrow sales.
- Express the company-specific execution thesis as long ASO / short HIBB over 3-6 months, sized modestly. Academy's store rollout and broader assortment can pressure HIBB's regional share, while the pair reduces broad discretionary-retail beta; cover the short if HIBB shows accelerating comps or ASO's new-store productivity misses plan.
- Do not underwrite the tariff benefit as recurring EPS. Set an earnings-quality alert for the next report: if adjusted EPS growth ex-tariff effects fails to outpace sales growth, reduce or avoid the long because the operating-leverage thesis is not validating.
- Monitor DKS holiday promotional cadence and ASO digital fulfillment metrics as leading indicators. A broad sporting-goods discount cycle would favor avoiding ASO despite traffic resilience, as its margin sensitivity is likely greater than the current guidance revision implies.
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Xencor reports phase 1 data for cancer drug XmAb819